Guide to Dengue Fever Vaccination for Children in Indonesia: Types, Effectiveness, and Estimated Costs
Vaccination is a crucial step in reducing dengue fever (DBD) cases among children in Indonesia. Currently, two main vaccines have received marketing authorisation: Qdenga (TAK-003) and Dengvaxia (CYD-TDV), each with different provisions based on prior infection history.
According to the Food and Drug Monitoring Agency (BPOM) and the Ministry of Health, Qdenga can be administered to individuals aged 4 to 60 years regardless of previous dengue infection history. This vaccine is given in two doses with a three-month interval. In contrast, Dengvaxia is intended for children aged 9 to 16 years who have already been infected with dengue (seropositive). Administering Dengvaxia to children who have never been infected risks increasing the severity of illness if they later contract dengue.
Phase 3 data shows Qdenga has an efficacy of 80.2% in preventing dengue and 95.4% in preventing hospitalisation. Reported side effects are generally mild to moderate, such as injection site pain, headache, muscle pain, and brief fever. However, the vaccine is not recommended for individuals with immune disorders, pregnant women, or breastfeeding mothers.
An important note: children who have previously had dengue are still advised to be vaccinated. This is because natural infection typically only provides immunity against one of the four dengue virus serotypes, leaving a risk of infection from the other serotypes.
Currently, the dengue vaccine is not included in the national free immunisation programme and is available independently at hospitals or private clinics. Based on price monitoring at various health facilities such as Mandaya Royal Hospital Puri and Pantai Indah Kapuk Hospital, the price per dose ranges from Rp600,000 to Rp1,000,000.
For complete protection with Qdenga (two doses), parents need to budget approximately Rp1.2 million to Rp2 million per child. This cost generally does not include doctor consultation fees, administrative charges, or initial screening costs. Even after vaccination, the public is urged to continue practising the 3M Plus protocol and personal protection against mosquito bites, as the vaccine does not provide 100% protection.
Source: jawawa.id (https://jawawa.id/newsitem/guide-to-dengue-fever-vaccination-for-children-in-indonesia-types-effectiveness-and-estimated-costs-1782982217)
Originally published by Media Indonesia (https://mediaindonesia.com/humaniora/906672/panduan-vaksin-dbd-anak-di-indonesia-jenis-efektivitas-dan-estimasi-biaya), translated from Indonesian